Calgary, Alberta, Canada
May 7, 2009
SemBioSys Genetics Inc. (TSX:SBS), specializing in the
manufacture of high-value proteins and oils in plant seeds, held
its Annual and Special Meeting of Shareholders on May 5th, 2009
at its corporate headquarters in Calgary, Alberta.
At the Meeting the shareholders re-elected Mr. Richard Smith,
Mr. Ian S. Brown, Dr. Alexander R. Giaquinto and Dr. Oye
Olukotun, and elected Mr. William H. Smith, Q.C. to serve as
Directors of the Company. Mr. James Szarko, CA was appointed to
the Board in January, when he was appointed President and CEO of
SemBioSys.
William (Bill) Smith, Q.C., has been involved in the start up or
initial phases of more than 30 companies in a variety of
industries, working with senior executives and Boards. He has
been a director of numerous public and
significant private business organizations. Bill has practiced
law for more than 30 years, including more than 20 years in the
Calgary Business Law Group of McCarthy Tetrault LLP. Mr. Smith
served as acting Chief Executive Officer of the Alberta
Securities Commission and chaired the Alberta Securities
Commission, Securities Advisory Committee from its inception for
10 years. In January 2000, he was appointed as Queen's Counsel
in recognition of his community activities.
Calgary, Alberta-based SemBioSys is a world leader in
manufacturing high-value proteins and oils in plant seeds. With
its unique, proprietary platform, SemBioSys provides partners
with product enablement, exceptionally low cost and
unprecedented scalability. The Company applies this platform
with high selectivity to opportunities where it has a unique
competitive advantage. Since its inception, SemBioSys has
produced more than 50 non-native proteins and oils using its
patented seed technology, demonstrating applicability across a
broad range of industries such as pharmaceuticals, personal care
and industrial products. The Company's current pharmaceutical
development programs include insulin (SBS-1000, regulated as a
biosimilar in Europe) and Apo AIMilano, a next-generation
cardiovascular therapy. SemBioSys is listed on the Toronto Stock
Exchange under the ticker SBS. |
|
